CAS NO: | 577778-58-6 |
包装 | 价格(元) |
10 mM * 1 mL in DMSO | 电议 |
10mg | 电议 |
25mg | 电议 |
50mg | 电议 |
100mg | 电议 |
200mg | 电议 |
500mg | 电议 |
生物活性 | Topiroxostat (FYX-051) is a potent and orally activexanthine oxidoreductase (XOR)inhibitor with anIC50value of 5.3 nM and aKivalue of 5.7 nM. Topiroxostat exhibits weakCYP3A4-inhibitory activity (18.6%). Topiroxostat has the potential for hyperuricemia treatment[1][2]. | ||||||||||||||||
IC50& Target | IC50: 5.3 nM (XOR)[1] | ||||||||||||||||
体外研究 (In Vitro) | These potent and more sustained effects of Topiroxostat (FYX-051, compound 39) have been confirmed by a crystallographic analysis of XOR-Topiroxostat complex. The cyano group of Topiroxostat has been reported to play an important role in the binding activity between Topiroxostat and XOR. This is attributable to the formation of a hydrogen bond between Asn 768 of XOR and the cyano group of Topiroxostat[1]. | ||||||||||||||||
体内研究 (In Vivo) | Topiroxostat (FYX-051; 0.03-10 mg/kg; oral administration; for 1 hour; male Wistar/ST strain rats) treatment shows a potent and long-lasting hypouricemic effect in a rat model of potassium oxonate-induced hyperuricemia[2].
| ||||||||||||||||
Clinical Trial | |||||||||||||||||
分子量 | 248.24 | ||||||||||||||||
性状 | Solid | ||||||||||||||||
Formula | C13H8N6 | ||||||||||||||||
CAS 号 | 577778-58-6 | ||||||||||||||||
中文名称 | 托匹司他 | ||||||||||||||||
运输条件 | Room temperature in continental US; may vary elsewhere. | ||||||||||||||||
储存方式 |
| ||||||||||||||||
溶解性数据 | In Vitro: DMSO : 23.5 mg/mL(94.67 mM;Need ultrasonic and warming) 配制储备液
* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 |